Norton Rose Fulbright Advised Citic Securities And HSBC On Lepu Biopharma’s Share Placement On Hong Kong Stock Exchange
Norton Rose Fulbright Advised Citic Securities And HSBC On Lepu Biopharma’s Share Placement On Hong Kong Stock Exchange
Global law firm Norton Rose Fulbright has advised Citic Securities and HSBC on the placement of new shares on the Hong Kong Stock Exchange for the biopharmaceutical company, Lepu Biopharma Co., Ltd.
Lepu Biopharma, with its global vision, focuses on oncology therapeutics. Its mission is to become an innovative leader in addressing the unmet medical needs of cancer patients through pioneering research and development.
Citic Securities and HSBC acted as the placing agents for Lepu Biopharma and have agreed to facilitate the placement of a maximum of 51,170,000 Placing Shares at the Placing Price of HK$4.58 per H share on the Hong Kong Stock Exchange. The net proceeds from the placement will be used by Lepu Biopharma to advance its research and development, conduct clinical trials, and support other corporate initiatives.
The multi-disciplinary team from Norton Rose Fulbright was led by Psyche Tai, Head of the Hong Kong office and Capital Markets Practice, along with Hong Kong-based Partners Doris Ng and Harold Tin. They were supported by Senior Associate Timothy Lam. The team provided comprehensive advice on all financial and capital market matters related to the transaction and placing agreement.
